Proton therapy for treatment of intracranial benign tumors in adults: A systematic review. (January 2019)

• Record Type: Journal Article
• Authors: Lesueur, Paul; Calugaru, Valentin; Nauraye, Catherine; Stefan, Dinu; Cao, Kim; Emery, Evelyne; Reznik, Yves; Habrand, Jean Louis; Tessonnier, Thomas; Chaikh, Abdulhamid; Balosso, Jacques; Thariat, Juliette
• Is Part Of: Cancer treatment reviews. Volume 72(2019)
• Page Start: 56
• Page End: 64
• Publication Date: 2019-01
• Subjects: Proton therapy -- Benign meningioma -- Neurinoma -- Para ganglioma -- Pituitary adenoma; Cancer -- Periodicals; Cancer -- Treatment -- Periodicals; Neoplasms -- therapy -- Periodicals; Cancer -- Périodiques; Cancer -- Traitement -- Périodiques; Cancer -- Treatment; Electronic journals; Periodicals; 616.99406
• DOI: 10.1016/j.ctrv.2018.11.004
• Languages: English
• ISSNs: 0305-7372

Abstract

Highlights: Proton therapy is an efficient alternative to photonic radiotherapy for the treatment of intra cranial or cervical benign tumors. For these tumors, proton therapy could reduce neurocognitive impairment and risk of radio-induced secondary cancers. Proton therapy achieves excellent local control with low toxicity rates. Large randomized trials are still needed to assess proton therapy clinical advantages in comparison with radiosurgery or intensity modulated radiotherapy. Abstract: Introduction: The depth-dose distribution of a proton beam, materialized by the Bragg peak makes it an attractive radiation modality as it reduces exposure of healthy tissues to radiations, compared with photon therapy Prominent indications, based on a long-standing experience are: intraocular melanomas, low-grade skull-base and spinal canal malignancies. However, many others potential indications are under investigations such as the benign morbid conditions that are compatible with an extended life-expectancy: low grade meningiomas, paragangliomas, pituitary adenomas, neurinomas craniopharyngioma or recurrent pleomorphic adenomas. Materials: Given the radiation-induced risk of secondary cancer and the potential neurocognitive and functional alteration with photonic radiotherapy, we systematically analyzed the existing clinical literature about the use of proton therapy as an irradiation modality for cervical or intracranial benign tumors. The aim of this review was to report clinical outcomes of adult patients with benign intracranial or cervical tumors treated with proton therapy and to discuss about potential advantages of proton therapy over intensity modulated radiotherapy or radiosurgery. Results: Twenty-four studies were included. There was no randomized studies. Most studies dealt with low grade meningiomas (n = 9). Studies concerning neurinoma (n = 4), pituitary adenoma (n = 5), paraganglioma (n = 5), or craniopharyngioma (n = 1) were fewer. Whatever the indication, long term local control was systematically higher than 90% and equivalent to series with conventional radiotherapy. Conclusion: Proton-therapy for treatment of adult benign intracranial and cervical tumors is safe. Randomized or prospective cohorts with long term cognitive evaluations are needed to assess the real place of proton-therapy in the treatment of adults benign head and neck tumors.